Trial Profile
Efficacy of Alirocumab in the arteriosclerotic biomarker changes after percutaneous coronary angioplasty (PCI).
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Jun 2018
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- 04 Jun 2018 New trial record